Original Research

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D

ClinicoEconomics and Outcomes Research 2017, 9:31-38

Published Date: 30 December 2016